TY - JOUR
T1 - Laboratory evaluation of antifungal agents
T2 - A brief overview
AU - Rinaldi, Michael G.
PY - 1992/3/1
Y1 - 1992/3/1
N2 - The increasing incidence and significance of human mycotic diseases has prompted concurrent interest in the development and evaluation of antifungal drugs. There has never been a period in medicine when the number of antimycotic agents, either commercially available or undergoing clinical investigation, is as great as at present. An integral part of new antimicrobial development is the laboratory evaluation, both in vivo and in vitro, of such agents. Each of these aspects of laboratory testing offers distinct limitations and advantages; however, such evaluation is critical for continued success in the quest for nontoxic, inexpensive, and efficacious antifungal agents.
AB - The increasing incidence and significance of human mycotic diseases has prompted concurrent interest in the development and evaluation of antifungal drugs. There has never been a period in medicine when the number of antimycotic agents, either commercially available or undergoing clinical investigation, is as great as at present. An integral part of new antimicrobial development is the laboratory evaluation, both in vivo and in vitro, of such agents. Each of these aspects of laboratory testing offers distinct limitations and advantages; however, such evaluation is critical for continued success in the quest for nontoxic, inexpensive, and efficacious antifungal agents.
UR - http://www.scopus.com/inward/record.url?scp=85047697890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047697890&partnerID=8YFLogxK
U2 - 10.1093/clinids/14.Supplement_1.S130
DO - 10.1093/clinids/14.Supplement_1.S130
M3 - Article
C2 - 1562685
AN - SCOPUS:85047697890
SN - 1058-4838
VL - 14
SP - S130-S133
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -